Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22785907 | 0.84 | CYP3A4 (0.56) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL1155555 | 0.84 | CYP3A4 (0.56) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL22785945 | 0.84 | CYP3A4 (0.56) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL7107427 | 0.82 | AOC3 (0.50) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL12777417 | 0.82 | AOC3 (0.50) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL5490219 | 0.82 | AOC3 (0.54) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL1520267 | 0.82 | AOC3 (0.54) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11536600 | 0.81 | AOC3 (0.53) | AOC3CYP3A4MAPK1KMT2AMEN1 | |
| SCHEMBL5493126 | 0.81 | AOC3 (0.53) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 | |
| SCHEMBL8712770 | 0.81 | AOC3 (0.53) | AOC3CYP3A4CYP2D6MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888012-B2 | Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound | AJINOMOTO CO., INC. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | AJINOMOTO CO., INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1346972-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-0792936-B1 | Process for the preparation of optically active 2-halo-1-(substituted phenyl) ethanol | MITSUBISHI CHEM CORP (JP) | 2003-01-29 | — | — | EP | disclosed |
| US-5841001-A | ALLOWING 2-HALO-1-(SUBSTITUTED PHENYL)ETHANOL TO CONTACT ENZYME STEREOSELECTIVELY CATALYZING ESTER INTERCHANGE IN PRESENCE OF CARBOXYLIC ANHYDRIDE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0792936-A2 | Process for the preparation of optically active 2-halo-1-(substituted phenyl) ethanol | Mitsubishi Chemical Corporation (JP) | 1997-09-03 | — | — | EP | disclosed |
| US-4147799-A | Process for reducing blood pressure and blocking β-adrenergic receptor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | DHPS, HDHD5, HYPK | AOC3 954/4885CYP3A4 791/4885CYP2D6 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.